CD4+ T cells play a dominant role in protection against new world leishmaniasis induced by vaccination with the P-4 amastigote antigen

Infection and Immunity

Volumn 73, Issue 6, 2005, Pages 3823-3827

  Kar, Sujata ^a   Metz, Christine ^b   McMahon Pratt, Diane ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Institute for Medical Research at North Shore LIJ   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; LYMPHOTOXIN; MACROPHAGE MIGRATION INHIBITION FACTOR; P4 AMASTIGOTE ANTIGEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; IN VITRO STUDY; LEISHMANIA; LEISHMANIA MEXICANA; LEISHMANIA PIFANOI; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN LEISHMANIASIS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; INTERFERON TYPE II; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 19744369918     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.6.3823-3827.2005     Document Type: Article

References (18)

1. Bacher, M., C. N. Metz, T. Calandra, K. Mayer, J. Chesney, M. Lohoff, D. Gemsa, T. Donnelly, and R. Bucala. 1996. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc. Natl. Acad. Sci. USA 93:7849-7854.
2. + T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection. Infect. Immun. 71:3172-3182.
3. Denkinger, C. M., M. Denkinger, J. J. Kort, C. Metz, and T. G. Forsthuber. 2003. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J. Immunol. 170:1274-1282.
4. Jin, F. S., R. J. Youle, V. G. Johnson, J. Shiloach, R. Fass, D. L. Longo, and S. H. Bridges. 1991. Suppression of the immune response to immunotoxins with anti-CD4 monoclonal antibodies. J. Immunol. 146:1806-1811.
5. Juttner, S., J. Bernhagen, C. N. Metz, M. Rollinghoff, R. Bucala, and A. Gessner. 1998. Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. J. Immunol. 161:2383-2390.
6. Khaskhely, N. M., M. Maruno, H. Uezato, A. Takamiyagi, S. T. Ramzi, K. M. Al-Kasem, K. Kariya, T. Toda, Y. Hashiguchi, E. A. Gomez Landires, and S. Nonaka. 2002. Low-dose UVB contributes to host resistance against Leishmania amazonensis infection in mice through induction of gamma interferon and tumor necrosis factor alpha cytokines. Clin. Diagn. Lab. Immunol. 9:677-686.
7. Koebernick, H., L. Grode, J. R. David, W. Rohde, M. S. Rolph, H. W. Mittrucker, and S. H. Kaufmann. 2002. Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 99:13681-13686.
8. Liew, F. Y., C. Parkinson, S. Millott, A. Severn, and M. Carrier. 1990. Tumour necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunology 69:570-573.
9. Nashleanas, M., S. Kanaly, and P. Scott. 1998. Control of Leishmania major infection in mice lacking TNF receptors. J. Immunol. 160:5506-5513.
10. Rachamim, N., and C. L. Jaffe. 1993. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150:2322-2331.
11. Rammensee, H., J. Bachmann, N. P. Emmerich, O. A. Bachor, and S. Stevanovic. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50:213-219.
12. Rammensee, H. G., K. Falk, and O. Rotzschke. 1993. Peptides naturally presented by MHC class I molecules. Annu. Rev. Immunol. 11:213-244.
13. Satoskar, A., and J. Alexander. 1995. Sex-determined susceptibility and differential IFN-gamma and TNF-alpha mRNA expression in DBA/2 mice infected with Leishmania mexicana. Immunology 84:1-4.
14. Satoskar, A. R., M. Bozza, M. Rodriguez Sosa, G. Lin, and J. R. David. 2001. Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect. Immun. 69:906-911.
15. Soong, L., S. M. Duboise, P. Kima, and D. McMahon-Pratt. 1995. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect. Immun. 63:3559-3566.
16. Soong, L., J. C. Xu, I. S. Grewal, P. Kima, J. Sun, B. J. Longley, Jr., N. H. Ruddle, D. McMahon-Pratt, and R. A. Flavell. 1996. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 4:263-273.
17. Wilhelm, P., U. Ritter, S. Labbow, N. Donhauser, M. Rollinghoff, C. Bogdan, and H. Korner. 2001. Rapidly fatal leishmaniasis in resistant C57BL/6 mice lacking TNF. J. Immunol. 166:4012-4019.
18. Xu, D., S. J. McSorley, L. Tetley, S. Chatfield, G. Dougan, W. L. Chan, A. Satoskar, J. R. David, and F. Y. Liew. 1998. Protective effect on Leishmania major infection of migration inhibitory factor, TNF-alpha, and IFN-gamma administered orally via attenuated Salmonella typhimurium. J. Immunol. 160:1285-1289.